Announcements
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
- Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
- Bavarian Nordic og CEPI indgår partnerskab om mpox-vaccinationer i Afrika
- Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
- Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
- Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic
- EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
More ▼
Key statistics
On Friday, Bavarian Nordic A/S (BV3:BER) closed at 24.71, -16.97% below its 52-week high of 29.76, set on Jun 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.87 |
---|---|
High | 24.74 |
Low | 23.63 |
Bid | 24.46 |
Offer | 25.20 |
Previous close | 23.83 |
Average volume | 1.32k |
---|---|
Shares outstanding | 78.12m |
Free float | 78.05m |
P/E (TTM) | 14.38 |
Market cap | 14.44bn DKK |
EPS (TTM) | 12.86 DKK |
Data delayed at least 15 minutes, as of May 31 2024 20:43 BST.
More ▼